Introduction
============

Leucine rich repeat LGI family member 3 (LGI3; formerly known as leucine-rich glioma inactivated 3) is a secretory protein member of the LGI family in vertebrates that has been identified to be highly expressed in the brain ([@b1-ol-0-0-10648]). LGI3 expression in the brain has been reported to be regulated at the transcription level by activating enhancer-binding protein 2 (AP-2) and neuronal restrictive silencer ([@b1-ol-0-0-10648]). Our previous studies demonstrated that LGI3 regulates exocytosis and the differentiation of neuronal cells ([@b2-ol-0-0-10648],[@b3-ol-0-0-10648]). LGI3 is expressed in the epidermal layer of the skin where it may act as a cutaneous cytokine ([@b4-ol-0-0-10648]). Our previous study found that LGI3 is secreted in response to ultraviolet B irradiation and protects keratinocytes ([@b4-ol-0-0-10648]). Additionally, we previously reported that LGI3 increases migration and differentiation of keratinocytes ([@b5-ol-0-0-10648],[@b6-ol-0-0-10648]) and melanocyte pigmentation ([@b7-ol-0-0-10648]).

Our previous studies revealed that LGI3 is expressed in adipose tissues and its expression is downregulated during adipogenesis and upregulated in adipose tissues in obesity ([@b8-ol-0-0-10648],[@b9-ol-0-0-10648]). Furthermore, one of our previous studies demonstrated that LGI3 attenuates adipogenesis through a disintegrin and metalloproteinase domain-containing protein (ADAM)23, which is one of the receptors for LGI3 (ADAM22 and ADAM23), and that LGI3 increases pro-inflammatory genes, including tumor necrosis factor-α (TNF-α) in macrophage cells ([@b9-ol-0-0-10648]). LGI3 negatively regulates adiponectin ([@b8-ol-0-0-10648]). LGI3 and TNF-α increase expression mutually through NF-κB, suggesting their positive cooperativity in promoting metabolic inflammation in obesity ([@b10-ol-0-0-10648]). We postulated that LGI3 is a pleiotropic cytokine and adipokine secreted by and acting at multiple cell types, and that LGI3 may be a pro-inflammatory cytokine that interacts with various cytokines, adipokines, chemokines and signaling proteins ([@b11-ol-0-0-10648]).

Our recent studies proposed that LGI3 may be involved in the cytokine network in cancer ([@b11-ol-0-0-10648]--[@b13-ol-0-0-10648]). Our recent study reported that LGI3 expression is associated with the prognosis of glioma ([@b13-ol-0-0-10648]). Furthermore, the expression levels and genetic variations of LGI3 may have potential prognostic roles in various types of cancer ([@b12-ol-0-0-10648]). The present study utilized integrative analyses of gene expression microarrays, gene product networks and patient cohorts, and presented evidence supporting the potential prognostic role of LGI3 in non-small cell lung cancer (NSCLC), which is the most common type of lung cancer affecting 85% of patients ([@b14-ol-0-0-10648]).

Materials and methods
=====================

### Gene expression microarray data

The mRNA expression microarray dataset was retrieved from the Gene Expression Omnibus database (<http://www.ncbi.nlm.nih.gov/geo/>). The dataset GSE19804 is based on the GPL570 \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix; Thermo Fisher Scientific, Inc.) platform ([@b15-ol-0-0-10648]). The dataset contained 120 samples, including 60 samples of NSCLC tissues and 60 samples of paired adjacent normal lung tissues from nonsmoking patients with NSCLC.

### Data processing for identification of differentially expressed genes (DEGs)

The microarray data were analyzed using the affy package (version 1.62.0) in R 3.5.1 (<http://www.r-project.org>) ([@b16-ol-0-0-10648]). The dataset was subjected to background correction, quantile normalization and probe summarization of expression values. The log2 intensities of the probeset were calculated by the Robust Multichip Average algorithm of the affy package ([@b16-ol-0-0-10648]). Gene expression data were averaged to provide the final expression values for multiple probes for the same gene symbols. Probesets to non-expressed mRNAs were excluded using the Affymetrix Microarray Suite 5 calls algorithm (version 5.0; [web.mit.edu/\~r/current/arch/i386_linux26/lib/R/library/affy/html/mas5calls.html](web.mit.edu/~r/current/arch/i386_linux26/lib/R/library/affy/html/mas5calls.html)). Differential expression analysis was conducted using the limma package (version 3.40.2; [bioconductor.org/packages/release/bioc/html/limma.html](bioconductor.org/packages/release/bioc/html/limma.html)) in R 3.5.1. Genes with P\<0.05 and \|log~2~ (fold change)\|≥1 were considered to be statistically significant DEGs.

### Comparative analysis, protein-protein interaction network, and functional enrichment and gene coexpression network (GCN) analyses of DEGs

Comparative analysis of categorized gene groups was presented using a Venn diagram generated by Venny 2.1 ([bioinfogp.cnb.csic.es/tools/venny](bioinfogp.cnb.csic.es/tools/venny)). The protein-protein interaction network was generated using data from the Search Tool for the Retrieval of Interacting Genes (version 10.5; [string-db.org](string-db.org)) ([@b17-ol-0-0-10648]), and was visualized by Cytoscape 3.7.0 using an interaction degree-sorted circle layout ([@b18-ol-0-0-10648]). Functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed using the Database for Annotation, Visualization and Integration Discovery (version 6.8; [david.abcc.ncifcrf.gov](david.abcc.ncifcrf.gov)) ([@b19-ol-0-0-10648]). Results were sorted by P-values and the subsets of the entries with P\<0.05 were presented. GCN analysis was performed using the GCN of human lung (uuid: 0c14bd70-5cae-11e7-8f50-0ac135e8bacf) ([@b20-ol-0-0-10648]) from The Network Data Exchange database (version 2.3.1; [www.ndexbio.org](www.ndexbio.org)) and visualized by Cytoscape 3.7.0 using the prefuse force directed layout. Gene Ontology (GO) terms of the GCN were mapped by BiNGO (version 3.0.3; [apps.cytoscape.org/apps/bingo](apps.cytoscape.org/apps/bingo)) and visualized by Cytoscape 3.7.0 using a hierarchical layout. Transcriptional regulatory associations between transcription factors and the groups of genes were analyzed by Transcription Factor Affinity Prediction tools ([trap.molgen.mpg.de](trap.molgen.mpg.de)) ([@b21-ol-0-0-10648]).

### Meta-analysis of patient cohorts

The datasets of gene expression microarray analysis for NSCLC cohorts were retrieved from the Prognoscan database (<http://www.prognoscan.org>; [Table III](#tIII-ol-0-0-10648){ref-type="table"}) ([@b22-ol-0-0-10648]). Datasets in the Prognoscan database were previously processed through quality control tests, normalization and batch effect adjustment and the exclusion of low-quality samples. The association between gene expression values and NSCLC prognosis was assessed by the minimum P-value method for survival analysis of patient groups that calculates the cut-point in a continuous gene expression measurement. Patients ranked by gene expression values were divided at the cut-off point to minimize the P-value, and the difference of survival between high and low gene expression groups was calculated using a log-rank test. The statistically significant (P\<0.05) datasets were used to generate Kaplan-Meier plots.

### Somatic mutations in NSCLC

Somatic mutations of the LGI3 gene in NSCLC were identified in Cbioportal ([www.cbioportal.org](www.cbioportal.org)), the Catalogue of Somatic Mutations in Cancer ([cancer.sanger.ac.uk/cosmic](cancer.sanger.ac.uk/cosmic)) and The Cancer Genome Atlas ([hportal.gdc.cancer.gov](hportal.gdc.cancer.gov)). Data of conserved residues, phylogenetically coevolved residues and single nucleotide polymorphisms (SNPs) of LGI3 have been previously described ([@b12-ol-0-0-10648]). A Venn diagram of the categorized genetic variations was generated using InteractiVenn ([www.interactivenn.net](www.interactivenn.net)).

Results
=======

### Differential expression of LGI3 in NSCLC

Our previous study reported that somatic mutations and expression of LGI3 may have prognostic significance in various types of cancer ([@b12-ol-0-0-10648]). Therefore, it was hypothesized that LGI3 may be associated with the cytokine network in lung cancer. In the present study, analysis of DEGs in the lung tissues from patients with NSCLC revealed that LGI3 expression was significantly lower than in normal tissues (fold change, 0.41; P=8.43×10^−20^; [Fig. 1](#f1-ol-0-0-10648){ref-type="fig"}). The expression levels of the LGI3 receptor ADAM22 were significantly decreased in NSCLC tissues (fold change, 0.72; P=7.01×10^−8^; [Fig. 1](#f1-ol-0-0-10648){ref-type="fig"}). Expression of ADAM23 was not significantly changed in NSCLC tissues ([Fig. 1](#f1-ol-0-0-10648){ref-type="fig"}).

### Identification of LGI3-regulated and NSCLC-altered genes, and their protein-protein interaction network

Analysis of DEGs in the expression microarray dataset of NSCLC revealed that 1,158 genes were upregulated and 1,526 genes were downregulated in NSCLC tissues (\|log~2~ (fold change)\|≥1 and P\<0.05). Our previous study identified 48 gene products that are regulated by LGI3 \[adiponectin (ADIPOQ), Akt1, BAD, complement C5 (C5), C-C motif chemokine ligand (CCL)2, CCL12, CD68, CCAAT enhance binding protein α, C-reactive protein (CRP), colony stimulating factor (CSF)1, CSF3, catenin β1, C-X-C motif chemokine ligand (CXCL)2, CXCL13, cytochrome b-24 α chain, cytochrome b-24 β chain, δ like non-canonical Notch ligand 1 (DLK1), eukaryotic translation initiation factor 4E binding protein 1, adhesion G protein-coupled receptor E1, endothelial cell specific molecule 1 (ESM1), fatty acid binding protein 4 (FABP4), glycogen synthase kinase 3 (GSK3)A, GSK3B, insulin like growth factor 1 (IGF1), IGF binding protein (IGFBP)1, IGFBP5, interleukin 6 (IL6), integrin subunit αX, lipoprotein lipase (LPL), mitogen-activated protein kinase (MAPK)1, MAPK3, MDM2 proto-oncogene (MDM2), microphthalmia-associated transcription factor (MITF), neutrophil cytosolic factor (NCF)1, NCF2, NF-κB1, nitric oxide synthase 2, PI3K catalytic subunit α, peroxisome proliferator activated receptor γ (PPARG), protein kinase AMP-activated catalytic subunit α1, PTEN, prostaglandin-endoperoxide synthase 2 (PTGS2), protein tyrosine kinase 2, serpin family E member 1 (SERPINE1), syntaxin 1A, TIMP metallopeptidase inhibitor 1 (TIMP1), TNF and tumor protein p53\] ([@b11-ol-0-0-10648]). Venn diagram analysis of NSCLC-altered and LGI3-regulated genes demonstrated that one LGI3-upregulated gene and one LGI3-downregulated gene belonged to the set of NSCLC-upregulated genes, and that seven LGI3-upregulated genes and four LGI3-downregulated genes belonged to the set of NSCLC-downregulated genes ([Fig. 2A](#f2-ol-0-0-10648){ref-type="fig"}). Overall, the expression levels of 27% (8/30) of the LGI3-upregulated genes and 28% (5/18) of the LGI3-downregulated genes were altered in NSCLC. Most of the LGI3-regulated gene products (94%; 45/48 genes) have been demonstrated to form a protein-protein interaction network cluster in our previous study ([@b11-ol-0-0-10648]). Protein-protein interaction network analysis of the 13 NSCLC-altered and LGI3-regulated genes demonstrated that all gene products formed an interaction network cluster ([Fig. 2B](#f2-ol-0-0-10648){ref-type="fig"}). The proteins with the highest interaction degrees (≥5) were CCL2 \[also known as monocyte chemoattractant protein (MCP-1)\], IL6, PPARG, SERPINE1, LPL and PTGS2 (also known as cyclooxygenase 2).

### Functional enrichment and KEGG pathway analyses of LGI3-regulated and NSCLC-altered genes

The functional signature of LGI3-regulated genes that are altered in NSCLC tissues was investigated by functional enrichment analysis to obtain the GO terms of the gene groups ([Table I](#tI-ol-0-0-10648){ref-type="table"}). The genes were significantly associated with immune and inflammatory processes, including lipopolysaccharide response, chemokines, vascular endothelial growth factor receptor, cell redox homeostasis and cell response to tumor necrosis factor. Additionally, KEGG pathway analysis of LGI3-regulated and NSCLC-altered genes revealed that the genes were associated with the signaling pathways of TNF, chemokines, PPAR, and cytokines and infectious diseases (i.e. malaria and leishmaniasis; [Table II](#tII-ol-0-0-10648){ref-type="table"}). All associated KEGG pathways were closely associated with immune and inflammatory systems.

### GCN analysis of LGI3-regulated and NSCLC-altered genes

To elucidate the roles of LGI3-regulated genes that are altered in NSCLC, this gene set was queried against the GCN of the lung. GCNs are a useful tool for exploring the roles of gene sets, since coexpressed genes are controlled by common transcriptional regulatory programs and are members of the same protein complex or signaling pathway ([@b23-ol-0-0-10648]). A total of 10 gene products in the gene set ([Fig. 2B](#f2-ol-0-0-10648){ref-type="fig"}) were found in the lung GCN (group a; [Fig. 3A](#f3-ol-0-0-10648){ref-type="fig"}) and these gene products were associated with 322 gene products in the network (groups b and c; [Fig. 3A](#f3-ol-0-0-10648){ref-type="fig"}). The subnetwork of coexpression, consisting of 322 gene products ([Table SI](#SD1-ol-0-0-10648){ref-type="supplementary-material"}), appeared to occupy a domain with two adjacent clusters in the GCN (groups b and c; [Fig. 3A](#f3-ol-0-0-10648){ref-type="fig"}). A GO category map of the subnetwork (groups b and c; [Fig. 3B](#f3-ol-0-0-10648){ref-type="fig"}) demonstrated that the gene products in the network were involved in immune (groups b and c) and inflammatory responses, including responses to wounding and stress (group c). Transcription factor affinity prediction of the genes in groups b and c suggested that these genes may be coexpressed under the common transcriptional regulatory processes by various immune and inflammatory transcription factors \[Elf-1, ETS variant 4 (Pea3), Spi-1 proto-oncogene (Pu.1), C-ets-1, upstream transcription factor (Usf) 1/2, Stat6, NF-κB (Rela), cAMP response element-binding protein (CREB) and AP-2; [Table SII](#SD1-ol-0-0-10648){ref-type="supplementary-material"}\].

### Association of LGI3 with prognosis of NSCLC

Downregulation of LGI3 in NSCLC tissues ([Fig. 1](#f1-ol-0-0-10648){ref-type="fig"}) suggested an association of LGI3 with the morbidity and mortality of NSCLC. To investigate the prognostic significance of LGI3 expression in NSCLC, gene expression microarray data of NSCLC patient cohorts were analyzed ([Table III](#tIII-ol-0-0-10648){ref-type="table"}). The results revealed that the NSCLC studies demonstrated a significant association (P\<0.05) of low LGI3 expression with poor prognosis of NSCLC ([Table III](#tIII-ol-0-0-10648){ref-type="table"}, [Fig. 4](#f4-ol-0-0-10648){ref-type="fig"}). Analysis of ADAM22 expression in the NSCLC cohorts revealed no consistent association between its expression and NSCLC prognosis (data not shown).

### Somatic mutations of LGI3 in NSCLC

The somatic mutations of the LGI3 gene in NSCLC with amino acid alterations were identified in two major types of NSCLC, lung adenocarcinoma and lung squamous cell carcinoma ([Table IV](#tIV-ol-0-0-10648){ref-type="table"}). A total of seven mutations with amino acid alterations were found in each NSCLC type, none of which occurred in both types of cancer. Venn diagram analysis of the amino acid variations in the five categories \[conserved residues, phylogenetically coevolved residues, SNPs ([@b12-ol-0-0-10648]) and somatic mutations in two types of NSCLC\] revealed that a subgroup of somatic mutation sites in NSCLC belonged to phylogenetically coevolved residues (Y293H in lung adenocarcinoma and A83V and L117F in lung squamous cell carcinoma) or SNP sites (S171stop and R430G in lung squamous cell carcinoma; [Fig. 5](#f5-ol-0-0-10648){ref-type="fig"}). The amino acid alterations (S171stop and R430G) at SNP sites were different from the residues of the minor SNP alleles (Leu171, Cys430) and were not found in somatic mutations in NSCLC ([@b12-ol-0-0-10648]). No somatic mutation was identified at conserved residues.

Discussion
==========

LGI protein members (LGI1, −2, −3 and −4) are differentially expressed in various tumor cells and LGI1 has been proposed to be a tumor suppressor gene in brain tumors ([@b24-ol-0-0-10648],[@b25-ol-0-0-10648]). Our previous studies on LGI3 indicated that somatic mutations in various types of cancer were found in the LGI3 gene and subsets of the mutations affected SNP sites, phylogenetically coevolved amino acids and a conserved amino acid ([@b12-ol-0-0-10648]). Additionally, our previous studies demonstrated that the expression levels of LGI3 in tumor tissues are associated with the prognosis of brain, colorectal and lung cancers ([@b12-ol-0-0-10648],[@b13-ol-0-0-10648]). It was postulated that LGI3 may interact with the cytokine network in cancer through its genetic variations and dysregulated expression ([@b11-ol-0-0-10648],[@b12-ol-0-0-10648]).

The present study explored the potential prognostic value and functional network of LGI3 in NSCLC using integrative analysis of gene expression microarray data and the LGI3-regulated cytokine network ([@b11-ol-0-0-10648],[@b12-ol-0-0-10648]). Significant decreases in the expression levels of LGI3 and one of its receptors, ADAM22, in NSCLC tissues suggested that LGI3 may be involved in NSCLC carcinogenesis and progression via its receptor-mediated signaling pathway. Mediators of cellular signaling of LGI3 identified in our previous studies were: Akt and focal adhesion kinase (FAK) in LGI3-promoted neurite outgrowth ([@b3-ol-0-0-10648]), p53 and MDM2 in LGI3-promoted cell protection in ultraviolet B-irradiated keratinocytes ([@b4-ol-0-0-10648]), β-catenin and GSK3B in LGI3-induced keratinocyte migration ([@b5-ol-0-0-10648]), MITF in melanogenesis ([@b7-ol-0-0-10648]), and PPARG, CCAAT-enhancer binding protein α and NF-κB in LGI3-regulated adipogenesis and metabolic inflammation ([@b9-ol-0-0-10648],[@b10-ol-0-0-10648]). Preadipocytes treated with LGI3 exhibit regulation of various signaling proteins (upregulated, Akt, AMP-activated protein kinase, Erk and PTEN; downregulated, eukaryotic translation initiation factor 4E binding protein 1, Bad and GSK3A) ([@b11-ol-0-0-10648]). The mediators of the LGI3-stimulated intracellular signaling pathway via ADAM22 should be addressed, and whether the signaling pathway is active and perturbed in NSCLC cells requires further investigation.

Our cumulative studies found multiple gene products that were regulated by LGI3 ([@b1-ol-0-0-10648]--[@b5-ol-0-0-10648],[@b7-ol-0-0-10648]--[@b11-ol-0-0-10648]). A majority of the LGI3-regulated gene products (45/48 gene products) belong to a protein-protein interaction network that includes 16 cytokines, adipokines or chemokines, including ADIPOQ, CCL2/MCP-1, CSF1, CRP, CXCL2, CXCL13, CSF3, C5/HC, ESM1, IGF1, IGFBP1, IGFBP5, IL6, CCL12, TIMP1 and TNF-α ([@b11-ol-0-0-10648]). Among the 13 LGI3-regulated and NSCLC-altered gene products that formed a cluster of protein-protein interaction network, five gene products belonged to the cytokines or chemokines (CCL2, CSF3, CXCL2, CXCL13 and IL6). These results suggested that dysregulation of LGI3 may account for perturbation of the cytokine network and cell-cell communication in the microenvironment of NSCLC.

LGI3-regulated and NSCLC-altered genes were analyzed by functional enrichment and KEGG pathway analyses, and were determined to be significantly associated with the immune and inflammatory responses, chemokines and cytokine activities. These results were distinct from the same analyses of the LGI3-regulated genes that were altered in glioma in that the gene products were more significantly associated with angiogenesis, apoptosis, hypoxia, proliferation, p53 and hypoxia-inducible factor-1 signaling pathways in glioma ([@b13-ol-0-0-10648]). Therefore, LGI3 may be involved in the pathogenesis of NSCLC and glioma through common and distinctive mechanisms.

All LGI3-regulated and NSCLC-altered genes were found in the previous literature on NSCLC that reported an association of genetic variations, expression and function of these genes with NSCLC. Expression levels of PTGS2 ([@b26-ol-0-0-10648]), IL6 ([@b27-ol-0-0-10648]), CCL2 ([@b28-ol-0-0-10648]), NCF1/2 ([@b29-ol-0-0-10648]), CXCL2 ([@b30-ol-0-0-10648]), CSF3 ([@b31-ol-0-0-10648]), CXCL13 ([@b32-ol-0-0-10648]), LPL ([@b33-ol-0-0-10648]), SERPINE1 ([@b34-ol-0-0-10648]), PPARG ([@b35-ol-0-0-10648]) and FABP4 ([@b36-ol-0-0-10648]), and the promoter methylation of DLK1 ([@b37-ol-0-0-10648]) have been reported to be associated with the prognosis and pathogenesis of NSCLC. A total of seven genes (PTGS2, IL6, CCL2, NCF2, CXCL2, CSF3 and NCF1) that have been reported to be increased by LGI3 may be downregulated in NSCLC due to the suppression of LGI3 expression. DLK1, which has been revealed to be decreased by LGI3 ([@b11-ol-0-0-10648]), may be increased in NSCLC due to downregulation of LGI3. Thus, it may be postulated that the perturbation of the expression of the eight genes (PTGS2, IL6, CCL2, NCF2, CXCL2, CSF3, NCF1 and DLK1) was predominantly influenced by LGI3 downregulation in NSCLC. LGI3 may functionally interact with these gene products through protein-protein interaction networks in the implicated mechanisms as determined by the functional enrichment and KEGG pathway analyses.

LGI3 is abundantly expressed in the lung as well as diverse tissues, including the brain, skin, adipose tissues, liver, muscle, kidney and pancreas ([@b1-ol-0-0-10648],[@b4-ol-0-0-10648],[@b9-ol-0-0-10648],[@b38-ol-0-0-10648]). LGI3 has been demonstrated to be expressed in a variety of cell types, including neurons, keratinocytes, melanocytes, adipocytes and macrophages ([@b3-ol-0-0-10648],[@b4-ol-0-0-10648],[@b9-ol-0-0-10648],[@b10-ol-0-0-10648]). The RNA-sequencing data of the lung from the Human Protein Atlas (<https://www.proteinatlas.org>) indicates that LGI3 transcripts are distributed in pneumocytes (20--40% of total transcripts per million), bronchial epithelium (5--10%), endothelial cells (20--35%) and macrophages (5--15%). LGI3-expressing cell types in the mouse lung (mouse single cell transcriptome database; <http://tabula-muris.ds.czbiohub.org>) are notably similar to the human lung, supporting the validity of mouse models in studying LGI3 in human lung cancer. GCN analysis of LGI3-regulated and NSCLC-altered gene products in the present study further supported the notion that LGI3 is involved in NSCLC prognosis and pathogenesis as a regulatory cytokine in tumor immunity and inflammation. The gene products in the subnetwork (groups b and c) connected by gene coexpression with LGI3-regulated and NSCLC-altered genes, were demonstrated to be associated with common transcriptional regulatory processes of immune and inflammatory transcription factors \[Elf-1 ([@b39-ol-0-0-10648]), Pea3 ([@b40-ol-0-0-10648]), Pu.1 ([@b41-ol-0-0-10648]), C-ets-1 ([@b42-ol-0-0-10648]), Usf1/2 ([@b43-ol-0-0-10648]), Stat6 ([@b44-ol-0-0-10648]), NF-κB ([@b45-ol-0-0-10648]), CREB ([@b46-ol-0-0-10648]), and AP-2 ([@b47-ol-0-0-10648])\]. Our previous study reported that NF-κB is a key transcription factor in mutual upregulation of LGI3 and TNF-α, implicated in adipose tissue inflammation in obesity ([@b10-ol-0-0-10648]). Thus, downregulation of LGI3 in NSCLC may serve a role in the perturbation of the immune and inflammatory GCN of the lung, and may account for prognostic mechanisms of NSCLC.

The association of LGI3 expression with the prognosis of NSCLC identified in the present study suggests that LGI3 may serve antitumor roles in NSCLC progression. LGI3 has been demonstrated to stimulate intracellular signaling proteins and transcription factors involved in cancer, including p53, MDM2, Akt, β-catenin, FAK, NF-κB and MITF ([@b3-ol-0-0-10648],[@b4-ol-0-0-10648],[@b7-ol-0-0-10648],[@b10-ol-0-0-10648],[@b48-ol-0-0-10648]--[@b50-ol-0-0-10648]). Dysregulation of these proteins by decreased LGI3 may be responsible for the prognostic role of LGI3 in NSCLC and glioma ([@b13-ol-0-0-10648]). Our previous study hypothesized that LGI3 may be a member of cytokine networks involved in obesity-associated metabolic disorders and cancer ([@b11-ol-0-0-10648]). Cytokine networks serve critical roles in anticancer immunity in the NSCLC microenvironment ([@b51-ol-0-0-10648]). By contrast, cytokine networks may promote tumor growth and metastasis through chronic inflammation ([@b52-ol-0-0-10648]). It was postulated that upregulated LGI3 in adipose tissue and plasma in obesity may promote chronic inflammation and cancer ([@b8-ol-0-0-10648],[@b9-ol-0-0-10648],[@b11-ol-0-0-10648]). Cytokine perturbation in obesity may increase the risk of cancer in the digestive system, including the liver, pancreas and gastrointestinal tract ([@b53-ol-0-0-10648]). Consistent association between obesity and NSCLC has not been reported in previous studies; however, previous reports have suggested that being overweight is a positive prognostic factor ([@b54-ol-0-0-10648],[@b55-ol-0-0-10648]). Thus, the LGI3-regulated adipokine network in obesity may not account for the LGI3-regulated cytokine network in NSCLC prognosis ([@b8-ol-0-0-10648],[@b10-ol-0-0-10648]).

Our previous studies indicated that LGI3 increased M1-polarized macrophage markers (TNF-α, inducible nitric oxide synthase, CCL2/MCP-1, CD11c and IL-6) ([@b9-ol-0-0-10648]--[@b11-ol-0-0-10648]). Macrophage polarization in the tumor microenvironment was investigated in NSCLC prognosis, and predominant M1 macrophages with inflammatory and antitumorigenic activities have been associated with a positive NSCLC prognosis ([@b56-ol-0-0-10648]). Thus, LGI3 may contribute to antitumor processes in the NSCLC microenvironment by promoting and maintaining M1-polarization of tumor-associated macrophages.

The somatic mutations of LGI3 in two major types of NSCLC suggested the potential prognostic value of the genetic variations of LGI3 in NSCLC. The mutations were distributed throughout the LGI3 protein domains (leucine-rich repeats and EPTP domains) and the residue 248 was the only site with multiple mutations (A248V and A248P). It was noted that two somatic mutations in lung squamous cell carcinoma (S171stop and R430G) were found at SNP sites with rare variants (global minor allele frequency, 0.0002) ([@b12-ol-0-0-10648]). These results warrant further studies on the prognostic and pathological roles of the genetic variations of LGI3 in NSCLC. Studies with LGI3-deficient or variant LGI3-expressing animal models and cell lines may provide further insight into the prognostic and pathological mechanisms of LGI3 in NSCLC.

In conclusion, the present study provided an integrative insight into the prognostic value of LGI3 in NSCLC by revealing the regulatory network of NSCLC-altered and LGI3-regulated gene products, and the association of expression and genetic variations of LGI3 with NSCLC. LGI3 may serve pathological as well as prognostic roles in NSCLC through its pro-inflammatory cytokine activity in immune and inflammatory processes of the tumor microenvironment.
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![Differential expression of LGI3 and its receptors in NSCLC tissues. Control (non-tumor) tissues are shown in white. NSCLC tissues are shown in grey. \*P\<0.001. ADAM, a disintegrin and metalloproteinase domain-containing protein; LGI3, leucine rich repeat LGI family member 3; NSCLC, non-small cell lung cancer.](ol-18-03-3388-g00){#f1-ol-0-0-10648}

![Comparative analysis of the up- and downregulated genes in NSCLC and LGI3-regulated genes. (A) Venn diagram showing the sets of the regulated gene categories. (B) Protein-protein interaction network of NSCLC-altered and LGI3-regulated products. The network includes nodes (gene products) and lines (pairwise protein interactions) sorted by interaction degrees. The symbols (\*, ^+^, ^\#^ and ^x^) indicate the gene products in the common sets of the regulated gene categories indicated in (A). CCL2, C-C motif chemokine ligand 2; CSF3, colony stimulating factor 3; CXCL, C-X-C motif chemokine ligand; DLK1, δ like non-canonical Notch ligand 1; FABP4, fatty acid binding protein 4; IL6, interleukin 6; LGI3, leucine rich repeat LGI family member 3; LPL, lipoprotein lipase; NCF, neutrophil cytosolic factor; NSCLC, non-small cell lung cancer; PPARG, peroxisome proliferator activated receptor γ; PTGS2, prostaglandin-endoperoxide synthase 2; SERPINE1, serpin family E member 1.](ol-18-03-3388-g01){#f2-ol-0-0-10648}

![GCN analysis of NSCLC-altered and LGI3-regulated gene products in the lung. (A) NSCLC-altered and LGI3-regulated gene products found in the lung coexpression network (group a), and the subnetwork of the gene group (groups b and c) coexpressed with the genes in group a. (B) Gene Ontology category map of the subnetwork consisting of group b and c genes. Letters above the circles that represent leaf nodes of the hierarchical tree indicated the groups of the subnetworks in (A). CCL2, C-C motif chemokine ligand 2; CSF3, colony stimulating factor 3; CXCL2, C-X-C motif chemokine ligand 2; FABP4, fatty acid binding protein 4; GCN, gene coexpression network; IL6, interleukin 6; LGI3, leucine rich repeat LGI family member 3; NCF, neutrophil cytosolic factor; NSCLC, non-small cell lung cancer; PPARG, peroxisome proliferator activated receptor γ; PTGS2, prostaglandin-endoperoxide synthase 2; SERPINE1, serpin family E member 1.](ol-18-03-3388-g02){#f3-ol-0-0-10648}

![Association of LGI3 expression with the prognosis of patients with non-small cell lung cancer. Kaplan-Meier curves of the (A) GSE31210, (B) GSE8894 and (C) GSE11117 datasets of patient groups. LGI3, leucine rich repeat LGI family member 3.](ol-18-03-3388-g03){#f4-ol-0-0-10648}

![Comparative analysis of the somatic mutations in non-small cell lung cancer and genetic variations of leucine rich repeat LGI family member 3. The Venn diagram indicates the distribution of amino acid residues in the categories of variations. \*Somatic mutations at phylogenetically coevolved amino acid residue 293. ^\#^Somatic mutations at phylogenetically coevolved amino acid residues 83 and 117. ^+^Somatic mutations at the amino acid residues with SNP sites (residues 171 and 430). SNP, single nucleotide polymorphism.](ol-18-03-3388-g04){#f5-ol-0-0-10648}

###### 

Functional enrichment analysis of leucine rich repeat LGI family member 3-regulated genes that are altered in non-small cell lung cancer.

  Category           Term                                                                        Count, n   P-value
  ------------------ --------------------------------------------------------------------------- ---------- -------------
  GOTERM_CC_DIRECT   GO:0005615\~extracellular space                                             8          1.37×10^−5^
  GOTERM_BP_DIRECT   GO:0050729\~positive regulation of inflammatory response                    4          2.19×10^−5^
  GOTERM_CC_DIRECT   GO:0005576\~extracellular region                                            8          4.41×10^−5^
  GOTERM_BP_DIRECT   GO:0071222\~cellular response to lipopolysaccharide                         4          8.08×10^−5^
  GOTERM_BP_DIRECT   GO:0006954\~inflammatory response                                           5          1.55×10^−4^
  GOTERM_BP_DIRECT   GO:0006955\~immune response                                                 5          2.33×10^−4^
  GOTERM_BP_DIRECT   GO:0009409\~response to cold                                                3          3.43×10^−4^
  GOTERM_MF_DIRECT   GO:0008009\~chemokine activity                                              3          6.31×10^−4^
  GOTERM_BP_DIRECT   GO:0070098\~chemokine-mediated signaling pathway                            3          1.33×10^−3^
  GOTERM_BP_DIRECT   GO:0048010\~vascular endothelial growth factor receptor signaling pathway   3          1.37×10^−3^
  GOTERM_BP_DIRECT   GO:0042493\~response to drug                                                4          1.47×10^−3^
  GOTERM_BP_DIRECT   GO:0045454\~cell redox homeostasis                                          3          1.57×10^−3^
  GOTERM_BP_DIRECT   GO:0071356\~cellular response to tumor necrosis factor                      3          3.16×10^−3^
  GOTERM_BP_DIRECT   GO:0019221\~cytokine-mediated signaling pathway                             3          4.45×10^−3^
  GOTERM_MF_DIRECT   GO:0008201\~heparin binding                                                 3          6.50×10^−3^
  GOTERM_BP_DIRECT   GO:0032496\~response to lipopolysaccharide                                  3          6.89×10^−3^
  GOTERM_BP_DIRECT   GO:0001525\~angiogenesis                                                    3          1.24×10^−2^
  GOTERM_MF_DIRECT   GO:0019899\~enzyme binding                                                  3          2.62×10^−2^
  GOTERM_MF_DIRECT   GO:0005102\~receptor binding                                                3          2.92×10^−2^
  GOTERM_BP_DIRECT   GO:0007186\~G-protein coupled receptor signaling pathway                    4          2.92×10^−2^
  GOTERM_BP_DIRECT   GO:0045944\~positive regulation of transcription from RNA pol II promoter   4          3.66×10^−2^
  GOTERM_BP_DIRECT   GO:0045087\~innate immune response                                          3          4.23×10^−2^

BP, biological process; CC, cellular component; GO, Gene Ontology; MF, molecular function.

###### 

Kyoto Encyclopedia of Genes and Genomes pathway analysis of leucine rich repeat LGI family member 3-regulated genes that are altered in non-small cell lung cancer.

  Term                                                  Count, n   P-value
  ----------------------------------------------------- ---------- ---------
  hsa04668: TNF signaling pathway                       4          0.00053
  hsa05144: Malaria                                     3          0.00260
  hsa04062: Chemokine signaling pathway                 4          0.00270
  hsa03320: PPAR signaling pathway                      3          0.00481
  hsa04060: Cytokine-cytokine receptor interaction      4          0.00493
  hsa05140: Leishmaniasis                               3          0.00539
  hsa05142: Chagas disease (American trypanosomiasis)   3          0.01129
  hsa04380: Osteoclast differentiation                  3          0.01754

hsa, *homo sapiens*; NOD, nucleotide binding oligomerization; PPAR, peroxisome proliferator activated receptor; TNF, tumor necrosis factor.

###### 

Dataset summary of expression microarray analyses for non-small cell lung cancer studies.

  Group^a^   Dataset    Array type             Number of patients, n   Cut-off point   P-value
  ---------- ---------- ---------------------- ----------------------- --------------- ---------
  A          GSE31210   HG-U133_Plus_2         204                     0.72            0.0098
  B          GSE8894    HG-U133_Plus_2         138                     0.22            0.0341
  C          GSE11117   Novachip human 34.5k     41                    0.83            0.0247

The groups correspond with the panels in [Fig. 4](#f4-ol-0-0-10648){ref-type="fig"}.

###### 

Somatic mutations of leucine rich repeat LGI family member 3 in NSCLC tissues.

  NSCLC type                Sample ID          Protein change                                       Mutation type   Chr 8 pos   Ref   Var   Allele freq (T)
  ------------------------- ------------------ ---------------------------------------------------- --------------- ----------- ----- ----- -----------------
  Adenocarcinoma            LUAD-5V8LT         S531C                                                Missense        22005729    T     A     NS
  Adenocarcinoma            LUAD-5V8LT         P530H                                                Missense        22005731    G     T     NS
  Adenocarcinoma            TCGA-44-2656--01   E507^[a](#tfn4-ol-0-0-10648){ref-type="table-fn"}^   Nonsense        22005801    C     A     0.21
  Adenocarcinoma            TCGA-91-6829-01    Q460L                                                Missense        22005941    T     A     0.16
  Adenocarcinoma            TCGA-55-A48X-01    G82R                                                 Missense        22012939    C     T     0.09
  Adenocarcinoma            TCGA-55-A490-01    L185V                                                Missense        22009455    G     C     0.40
  Adenocarcinoma            TCGA-83-5908-01    Y293H                                                Missense        22006443    A     G     0.32
  Squamous cell carcinoma   TCGA-66-2795-01    L117F                                                Missense        22012074    G     A     0.47
  Squamous cell carcinoma   TCGA-52-7810-01    S171^[a](#tfn4-ol-0-0-10648){ref-type="table-fn"}^   Nonsense        22009496    G     C     0.51
  Squamous cell carcinoma   TCGA-92-8065-01    E78K                                                 Missense        22012951    C     T     0.24
  Squamous cell carcinoma   TCGA-NC-A5HF-01    A83V                                                 Missense        22012935    G     A     0.38
  Squamous cell carcinoma   TCGA-85-8287-01    A248V                                                Missense        22009088    G     A     0.16
  Squamous cell carcinoma   TCGA-85-8287-01    A248P                                                Missense        22009089    C     G     0.17
  Squamous cell carcinoma   TCGA-66-2785-01    R430G                                                Missense        22006032    G     C     0.25

Stop; Allele freq (T), variant allele frequency in tumor; Chr 8 pos, chromosome 8 position; NS, not specified; NSCLC, non-small cell lung cancer; Ref, reference sequence; Var, variant sequence.
